Our research team is primarily focused on virus discovery using virus-metagenomics, isolation, and pathological genetic characterization and host protein-directed antiviral discovery, gene delivery-based antiviral discovery for emerging and re-emerging viruses. Accordingly, we have performed genetic and pathological characterization of Newcastle disease virus genotype VIIi, and genotype III Japanese Encephalitis Virus (JEV), and identified PARP1 inhibition protects mice against Japanese encephalitis virus infection using the PARP1-knockout mice model and CRISPR/Cas9 mediated KO-cells, siRNA/shRNA-mediated genetic knockdown and Adenovirus-mediated over expression models. In addition, we delivered the SIRT2 mice brain using Adeno-associated virus delivery for the therapeutic purpose against JEV. Similarly, we have disclosed the Beak and Feather Disease Virus to be host-specific, classified the newly discovered CRESS-DNA Viruses, generated the proof of concept of the Torque Teno Virus being a Naked DNA Particle without a virion structure, and identified Human Endogenous Retrovirus K113 as severity biomarkers of SARS‐CoV‐2. Our study reported the gain of novel spike protein (S1-NTD) in the pandemic SARS-CoV-2, and genetic variations in pandemic Omicron BA.2, BA.3, BA.4, and BA.5 of SARS-CoV-2. Specifically, we reported point mutations to accumulate in pandemic Mpoxv-Clade-IIb-A, and B.1 lineages through selection pressure.